Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 2Terminated 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 484Carcinoma, Non-Small-Cell Lung 440Prostatic Neoplasms 292Lung Neoplasms 170Stomach Neoplasms 140Neoplasms 114Squamous Cell Carcinoma of Head and Neck 109Neoplasm Metastasis 97Head and Neck Neoplasms 96Esophageal Neoplasms 71Ovarian Neoplasms 57Pancreatic Neoplasms 42Urinary Bladder Neoplasms 39Sarcoma 39Nasopharyngeal Carcinoma 36Carcinoma, Squamous Cell 30Triple Negative Breast Neoplasms 28Carcinoma, Ovarian Epithelial 28Adenocarcinoma of Lung 27Adenocarcinoma 27Esophageal Squamous Cell Carcinoma 25Parkinson Disease 4, Autosomal Dominant Lewy Body 23Carcinoma, Transitional Cell 23Adenocarcinoma Of Esophagus 23Breast Neoplasms, Male 22Recurrence 21Unspecified Adult Solid Tumor, Protocol Specific 20Inflammatory Breast Neoplasms 20Fallopian Tube Neoplasms 20Melanoma 18

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hormone Refractory Prostate Cancer × Docetaxel × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00313482 2012-05-11

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Veeda Oncology

Phase 2 Terminated
35 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated
134 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00795171 2010-08-18

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Medical University of Vienna

Phase 2 Unknown
60 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡